Hyaluronate and large molecular weight proteoglycans in synovial fluid from horses with various arthritides.

This research investigated the presence of large molecular weight proteoglycans and hyaluronate in the joint fluid of horses with different types of arthritis, offering insight into the potential use of these compounds as markers for diagnosing specific arthritic conditions.

Research Methodology and Sample Selection

• The study examined horses exhibiting acute (less than 2 weeks) or chronic (more than 4 weeks) lameness. These horses underwent a series of examinations, including clinical examination, intrasynovial anesthesia, radiography, arthroscopy, and synovial fluid analysis.
• The researchers grouped joints according to diagnosis. These groups included acute traumatic arthritis, chronic traumatic arthritis (with a degenerative joint disease subgroup), intra-articular fracture, and infectious arthritis.
• The study sample was sizeable, featuring 31 horses with arthritis and 9 control horses, contributing a total of 43 synovial fluid samples for analysis.

Analysis Technique and Results

• The researchers used high-performance liquid chromatography to measure the concentration of large molecular weight proteoglycans (PGs) and hyaluronate (HA) in the synovial fluid samples.
• Notably, a PG peak was detected in 8 of 23 SF samples from joints suffering chronic traumatic arthritis. The same was true for joints displaying intra-articular fractures and one with resolving infectious arthritis. Acute traumatic arthritis and control joints, however, showed no such peak.
• There was also a significant difference in the mean HA concentration between control joints and those with chronic traumatic arthritis.

Study Conclusions

• Large molecular weight PG fragments are released into equine synovial fluid during articular disease, and these can be detected simultaneously with hyaluronate using high-performance liquid chromatography.
• Significantly, the HA concentration in synovial fluid can serve as a diagnostic marker for chronic traumatic arthritis, highlighting its potential as a theoretically useful clinical tool.
• However, the concentration of PGs (or any other marker) in synovial fluid could not be reliably used to diagnose or monitor degenerative joint disease, suggesting the need for further research to identify adequate biomarkers for this condition.